KZIA Projected Dividend Yield
ADR (Sponsored)/Kazia Therapeutics Ltd ( NASDAQ : KZIA )Kazia Therapeutics Limited is an oncology focused drug development company. Co. is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. 20 YEAR PERFORMANCE RESULTS |
KZIA Dividend History Detail KZIA Dividend News KZIA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |